R-ICE (Rituximab + Ifosfamide + Carboplatin + Etoposide) × 2-3 cycles → ASCT in CR2 (r/r Burkitt salvage)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | None declared |
|---|
| ID | REG-RICE-BURKITT |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-BURKITT-2024 SRC-NCCN-BCELL-2025 |
Notes
R-ICE is established salvage for r/r aggressive B-cell NHL (DLBCL, Burkitt, transformed FL). For Burkitt specifically — extremely poor natural history at relapse (~3-6 mo OS), rapid intervention with CNS-active intensive salvage critical. CR2 with ASCT consolidation provides ~30-40% durable remission in fit younger r/r Burkitt; alloSCT preferred for primary-refractory or post-ASCT relapse. CNS-disease at relapse common — IT therapy mandatory + consider HD-MTX intensification. R-DHAP (cisplatin-based) is non-cross-resistant alternative if R-ICE fails. CAR-T (axi-cel ZUMA-7-like data) emerging for r/r aggressive B-NHL — not yet Burkitt-validated but mechanistically applicable.
Used By
Indication
IND-BURKITT-2L-RICE-ASCT- IND-BURKITT-2L-RICE-ASCT